Sagimet Biosciences
Gregory Duke has worked in the field of biosciences for over 25 years. Gregory began their career in 1994 at Aviron as a Scientist III. In 2002, they joined MedImmune Vaccines as a Principal Scientist. In 2012, they were appointed Senior Director of Research at 3-V Biosciences.
Gregory Duke obtained their Doctor of Philosophy (Ph.D.) in Biochemistry from the University of Wisconsin-Madison in 1989.
This person is not in any offices
Sagimet Biosciences
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways.